ReviewFrontiers in oncology2025
Recent progress in serine metabolism reprogramming in tumors and strategies for serine deprivation.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Direct comparison of serine restriction on the viability of normal and cancer cells demonstrates that methionine restriction is more cancer specific.Frontiers in oncology · 2026Article
- Metabolic remodeling and immune evasion in glioblastoma: a focus on serine and lipid networks.Frontiers in oncology · 2026Review
- The "serine code" of metabolic reprogramming: multidimensional roles of the serine synthesis pathway in tumors and novel breakthroughs for targeted therapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor cells undergo extensive metabolic reprogramming during malignant proliferation, with serine-a key nonessential amino acid-playing multiple roles in tumor metabolism. To maintain high serine levels, tumor cells upregulate phosphoglycerate dehydrogenase to enhance endogenous synthesis and concurrently increase exogenous uptake. Serine deprivation demonstrates antitumor potential across various malignancies; however, its clinical application remains limited by inadequate tumor selectivity and systemic toxicity. Recent advances in nanodelivery systems offer precise strategies to modulate tumor serine metabolism. Serine deprivation via these systems improves tumor-specific targeting while minimizing off-target toxicity to normal tissues. Therefore, this review aims to outline serine metabolism and its regulatory networks, evaluate the therapeutic potential and limitations of serine deprivation, and highlight recent advances in nanodelivery strategies targeting serine metabolism for cancer therapy, thereby providing insights for the development of novel anticancer approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.